192 related articles for article (PubMed ID: 32409139)
1. NF-κB in the New Era of Cancer Therapy.
Eluard B; Thieblemont C; Baud V
Trends Cancer; 2020 Aug; 6(8):677-687. PubMed ID: 32409139
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
3. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
Leone RD; Powell JD
Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
[TBL] [Abstract][Full Text] [Related]
4. HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
Carosella ED; Gregori S; Tronik-Le Roux D
Trends Cancer; 2021 May; 7(5):389-392. PubMed ID: 33563576
[TBL] [Abstract][Full Text] [Related]
5. Metabolic reprogramming of terminally exhausted CD8
Guo Y; Xie YQ; Gao M; Zhao Y; Franco F; Wenes M; Siddiqui I; Bevilacqua A; Wang H; Yang H; Feng B; Xie X; Sabatel CM; Tschumi B; Chaiboonchoe A; Wang Y; Li W; Xiao W; Held W; Romero P; Ho PC; Tang L
Nat Immunol; 2021 Jun; 22(6):746-756. PubMed ID: 34031618
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
8. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
[TBL] [Abstract][Full Text] [Related]
9. Turning Cold into Hot: Firing up the Tumor Microenvironment.
Duan Q; Zhang H; Zheng J; Zhang L
Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
[TBL] [Abstract][Full Text] [Related]
10. Translational Control of Immune Evasion in Cancer.
Suresh S; O'Donnell KA
Trends Cancer; 2021 Jul; 7(7):580-582. PubMed ID: 33972197
[TBL] [Abstract][Full Text] [Related]
11. Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy.
Liu Y; Leslie PL; Zhang Y
Trends Cancer; 2021 Mar; 7(3):226-239. PubMed ID: 33199193
[TBL] [Abstract][Full Text] [Related]
12. NF-κB and Its Role in Checkpoint Control.
Betzler AC; Theodoraki MN; Schuler PJ; Döscher J; Laban S; Hoffmann TK; Brunner C
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486375
[TBL] [Abstract][Full Text] [Related]
13. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
14. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
15. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
16. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
17. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
18. Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors.
Xiao L; Yeung H; Haber M; Norris MD; Somers K
Trends Cancer; 2021 Aug; 7(8):751-777. PubMed ID: 34183305
[TBL] [Abstract][Full Text] [Related]
19. The adenosine pathway in immuno-oncology.
Allard B; Allard D; Buisseret L; Stagg J
Nat Rev Clin Oncol; 2020 Oct; 17(10):611-629. PubMed ID: 32514148
[TBL] [Abstract][Full Text] [Related]
20. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]